Price
$3.56
Increased by +0.85%
Dollar Volume
136.52 K
ADR%
5.71
Earnings Report Date (estimate)
Mar 27, 23 (N/A)
Market Cap.
19.53 M
Shares Float
4.44 M
Shares Outstanding
5.49 M
Beta
0.94
Price / Earnings
-1.93
BPR
3.83
20D Range
3.28 3.84
50D Range
3.28 6.57
200D Range
3.28 10.20
  • Quarterly Earnings
  • Annual Earnings
Reported Date EPSChange YoY EstimateSurprise
Nov 17, 22 -1.17
Decreased by -223.18 K%
-0.77
Decreased by -51.95%
Nov 10, 22 -1.17
Increased by +99.94%
-0.77
Decreased by -51.95%
Aug 12, 22 -1.18
Increased by +99.99%
-0.68
Decreased by -73.53%
May 16, 22 -0.04
Increased by +100.00%
-0.02
Decreased by -100.00%
Nov 10, 21 -0.00
Increased by +100.00%
-0.03
Increased by +98.25%
Nov 15, 10 -1.94 K
Increased by +7.69%
-2.42 K
Increased by +20.00%
Sep 30, 10 -10.66 K
Decreased by -200.00%
-13.59 K
Increased by +21.57%
Aug 17, 10 -2.42 K
Increased by +79.02%
-2.42 K
  • Quarterly Financials
  • Annual Financials
Fiscal ending date RevenueChange YoY IncomeChange YoY ProfitChange YoY
Sep 30, 22 0.00
Decreased by N/A%
-6.24 M
Decreased by -13.17 K%
Decreased by N/A%
Decreased by N/A%
Jun 30, 22 0.00
Decreased by N/A%
-5.08 M
Decreased by -275.52%
Decreased by N/A%
Decreased by N/A%
Mar 31, 22 0.00
Decreased by N/A%
-3.54 M
Increased by +10.78%
Decreased by N/A%
Decreased by N/A%
Dec 31, 21 0.00
Decreased by N/A%
-1.81 M
Decreased by -655.21%
Decreased by N/A%
Decreased by N/A%
Sep 30, 21 0.00
Decreased by N/A%
-47.00 K
Increased by +97.67%
Decreased by N/A%
Decreased by N/A%
Jun 30, 21 0.00
Decreased by N/A%
-1.35 M
Increased by +41.55%
Decreased by N/A%
Decreased by N/A%
Mar 31, 21 0.00
Decreased by N/A%
-3.96 M
Increased by +52.45%
Decreased by N/A%
Decreased by N/A%
Dec 31, 20 0.00
Decreased by -100.00%
326.00 K
Decreased by -66.50%
Increased by +N/A%
Increased by +N/A%
  • Top 20 ETF Stock Exposure
  • Top 20 Institutional Holders
  • Top 20 Mutual Fund Holders
Rank ETF Shares Market Value Weight % in ETF
Open dropdown content
Open dropdown content
DAILY
WEEKLY
MONTHLY

AIkido Pharma Inc., a biotechnology company, focuses on developing small-molecule anti-cancer therapeutics. The company's pipeline of therapeutics includes therapies for prostate cancer, pancreatic cancer, acute myeloid leukemia (AML), and acute lymphoblastic leukemia. It is developing DHA-dFdC, a pancreatic drug candidate; and KPC34, a small molecule treatment for acute myeloid leukemia and acute lymphoblastic leukemia. The company is also developing an antiviral platform that inhibits replication of viruses, including influenza virus, Ebolavirus and Marburg virus, SARS-CoV, MERS-CoV, and SARS-CoV-2. It has license agreements with the University of Texas, University of Maryland Baltimore, Silo Pharma Inc., and Wake Forest University Health Sciences. The company was formerly known as Spherix Incorporated and changed its name to AIkido Pharma Inc. in March 2021. AIkido Pharma Inc. was founded in 1967 and is headquartered in New York, New York.